Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 10/20 | 0.45 |
| ▸ | PTGER1 | P34995 | 4/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.44 |
| ▸ | GLP1R | P43220 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6487037 | 0.92 | MRGPRX4 (0.46) | P2RX3MRGPRX4PPARGLMNASMN1; SMN2 | |
| SCHEMBL6502677 | 0.91 | P2RX3 (0.40) | P2RX3PTGER1MRGPRX4 | |
| SCHEMBL6489657 | 0.84 | KDM4C (0.42) | P2RX3MRGPRX4PPARG | |
| SCHEMBL6501562 | 0.84 | NR4A2 (0.57) | MRGPRX4PPARG | |
| SCHEMBL7200058 | 0.84 | FABP3 (0.48) | PTGER1MRGPRX4LMNASMN1; SMN2 | |
| SCHEMBL6491685 | 0.83 | FABP3 (0.46) | PTGER1MRGPRX4LMNASMN1; SMN2 | |
| SCHEMBL6495987 | 0.82 | PIK3C2B (0.41) | P2RX3PTGER1MRGPRX4PPARGLMNA | |
| SCHEMBL6489601 | 0.81 | NPSR1 (0.41) | PTGER1MRGPRX4PPARGLMNASMN1; SMN2 | |
| SCHEMBL6491606 | 0.80 | MRGPRX4 (0.41) | P2RX3PTGER1MRGPRX4 | |
| SCHEMBL6489915 | 0.80 | NR4A2 (0.46) | P2RX3MRGPRX4PPARGLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| WO-2004108686-A2 | BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | P2RX3 2660/4885PTGER1 1980/4885MRGPRX4 2443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.